

Clinical outcome of patients with high-risk endometrial carcinoma after treatment with chemotherapy only

Elisabeth Smogeli^{1, 2}, Milada Cvancarova³, Yun Wang¹, Ben Davidson^{2, 5}, Gunnar Kristensen^{1, 6}, Kristina Lindemann^{1, 2}

¹Department of Gynaecological Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

³Department of Nursing and Health Promotion, Faculty of Health Science, Oslo and Akershus University College of Applied Sciences, Oslo, Norway

⁵Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

⁶Institute for Cancer Genetics and Informatics, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Corresponding author:

Kristina Lindemann, Department of Gynaecological Oncology, Division of Cancer Medicine, Oslo University Hospital, PB 4953 Nydalen 0424 Oslo, Norway

Phone: (47) 22934000 fax: (47) 22934771

Email: klinde@ous-hf.no

Key Words: Endometrial cancer, high-risk, adjuvant chemotherapy, radiotherapy, recurrence, survival

Highlights

- Adjuvant chemotherapy without radiation yields acceptable disease free- and overall survival
- Very few local or loco-regional recurrences detected despite omission of radiotherapy
- Prognosis remains poor for patients with node-positive disease

PRECIS

Surgery followed by chemotherapy only for high-risk endometrial cancer yields acceptable disease free- and overall survival, with few loco-regional recurrences.

1 **ABSTRACT**

2 **Objectives:** Adjuvant treatment of high-risk endometrial cancer (EC) is still
3 controversial. Several studies have tried to clarify the best treatment strategy, and
4 guidelines have been made, but no study to date has shown a survival benefit for
5 radiation over chemotherapy. We aimed to evaluate the outcome of high-risk EC
6 patients treated with adjuvant chemotherapy only in a population where the routine
7 administration of adjuvant radiotherapy was omitted.

8 **Methods/Materials:** This is a retrospective study including 230 EC patients with
9 FIGO stage I type II, Ib type I/G3, stage II and IIIc treated at the Oslo University
10 Hospital between 2005-2012. Standard treatment was hysterectomy, bilateral
11 salphingo-ooforectomy and at least pelvic lymphadenectomy followed by adjuvant
12 chemotherapy.

13 **Results:** Of the 230 high-risk patients patients, standard treatment was given to 146
14 patients (63.5%); 60 patients in stage I, 10 patients in stage II and 76 patients in stage
15 IIIc. Only 10% of patients with stage I disease relapsed, with 3.3% loco-regional
16 relapses and 6.7% distant relapses. Recurrence rate in stage IIIc was 39.5%, with
17 7.9% isolated vaginal and 31.6% distant relapses. The 3-year DFS was 92% for stage
18 I, 80% for stage II and 60% for stage IIIc disease. In the total population, 55 patients
19 had FIGO stage Ia, 43 Ib, 42 stage II, and 90 IIIc disease. Recurrence rate in the total
20 population was 29.6%, with 9.6% isolated vaginal recurrences, 1.7% recurrences
21 located in the pelvis and 18.3% distant recurrences.

22 **Conclusions:** Patients with high-risk EC have acceptable vaginal/pelvic control rates
23 after adjuvant chemotherapy. However, prognosis remains poor for patients with
24 stage IIIc disease, also after chemotherapy.

1 INTRODUCTION

2 Endometrial cancer (EC) is the most common gynecological malignancy in the
3 Western world. The continuously increasing incidence in Western countries is mostly
4 attributable to the increase in prevalence of risk factors in the population such as
5 obesity and diabetes¹. Patients with early stage disease often have excellent
6 prognosis, with a 10-year overall survival rate exceeding 80%. Still, there are
7 subgroups with a high risk for occult micro-metastatic disease. Traditionally,
8 endometrial cancers have been considered to be resistant to chemotherapy and
9 most high-risk patients have been treated with adjuvant radiotherapy (RT). This view
10 has gradually changed since the publication of GOG-122 reporting improved both
11 disease-free survival (DFS) and overall survival (OS) for this group of patients after
12 chemotherapy compared to whole abdominal irradiation (WAI) in patients with stage
13 III and IV endometrial cancer². Since then, several randomized studies have tried to
14 clarify the role of adjuvant chemotherapy in endometrial cancer. Three subsequent
15 studies compared combination chemotherapy with adjuvant radiation to the pelvis in
16 patients with early stage high-risk or advanced stage disease. All three studies failed
17 to show significant differences in DFS or OS between the arms³⁻⁵ but they were not
18 designed to potentially identify a subgroup of patients that may benefit from either of
19 the treatment modalities.

20 In a pooled analysis of two randomized trials (NSGOEC-9501/EORTC-55991 and
21 MaNGO ILIAD-III) it was shown that the addition of chemotherapy sequential to RT
22 versus RT alone significantly increased DFS while the increase in OS did not reach
23 statistical significance⁶. The combined treatment was associated with increased
24 morbidity and a higher rate of treatment discontinuation. There was no significant
25 difference in the patterns of relapse between the arms. A large randomized study
26 (GOG 258) failed to show a difference in survival between chemotherapy versus
27 chemoradiation followed by chemotherapy in optimally debulked stage III and IV⁷.
28 The randomized Portec 3 study randomized patients in stage I, II and III without
29 residual disease to radiation alone or chemoradiation followed by chemotherapy. The
30 benefit in 5-year failure free survival with the combination was mainly driven by the
31 positive results for patients with stage III disease, but did not translate into a benefit
32 in overall survival⁸. Despite these studies, newly released ESGO guidelines^{9,10}
33 advocate for the administration of adjuvant radiotherapy in high-risk disease.

1 There have been constant concerns about the potentially increased risk of
2 pelvic/vaginal relapse in patients treated with chemotherapy only. In a retrospective
3 study where patients with stage IIIC disease treated with either chemotherapy alone,
4 radiation alone or a combination of both, pelvic relapse rates were 39%, 29% and
5 27%, respectively¹¹. However, most relapses in high-risk EC patients occur outside
6 the pelvis irrespective of the kind of adjuvant treatment¹¹. Vaginal recurrences can be
7 effectively salvaged by modern radiotherapy¹² and the omission of adjuvant
8 radiotherapy at least in early stage EC has not been shown to diminish long-term
9 survival¹³.

10 At the Norwegian Radium Hospital, patients with high-risk stage I/II and IIIC EC have
11 since 2005 therefore routinely been treated with chemotherapy only, omitting
12 radiotherapy. Here we report the oncological outcomes of this treatment policy.

13

14 **MATERIAL AND METHODS**

15

16 **Patients and follow-up**

17 This is an institutional retrospective study of a cohort of all endometrial cancer
18 patients, treated at the Oslo University Hospital (The Norwegian Radium Hospital,
19 Ullevål University Hospital and Rikshospitalet) between November 2005 and October
20 2012. Patients were selected from a validated quality assurance database, providing
21 detailed information on the primary diagnosis, the preoperative work-up, comorbidity,
22 surgical treatment, adjuvant treatment, incident relapse and localization of relapse.

23 All specimens underwent central histopathological review by a pathologist
24 specialized in gynecologic pathology at the Norwegian Radium Hospital at the time of
25 diagnosis. Individual survival data were available through linkage to Statistics Norway.
26 Stage of the disease at initial surgery was recoded to match the International
27 Federation of Gynecology and Obstetrics (FIGO) 2009 revised staging¹⁴. We
28 included all patients with (1) FIGO stage I, grade 3, endometrioid endometrial
29 carcinoma with myometrial invasion $\geq 50\%$, (2) FIGO stage I serous and clear cell
30 endometrial cancer (pure or mixed with at least 50% serous or clear cell component)
31 of any myometrial invasion, (3) endometrial cancer with cervical stromal invasion of
32 any histology (FIGO stage II) and (4) lymph node positive endometrial cancer of any
33 histology (FIGO stage IIIC). Patients with positive lymph nodes were further analyzed
34 according to histological subtype (grade 1 or 2 endometrioid adenocarcinoma versus

1 grade 3 endometrioid adenocarcinoma or serous and clear cell carcinomas).
2 Sarcomas or carcinosarcomas were excluded from the analyses, as well as patients
3 with synchronous ovarian cancer (n=6) or neoadjuvant chemotherapy (n=4). All
4 patients underwent surgical treatment with at least total hysterectomy and bilateral
5 salpingo-oophorectomy. Institutional guidelines considered standard treatment to be
6 pelvic lymphadenectomy and para-aortic lymphadenectomy up to the renal veins for
7 high-risk stage I, omentectomy for serous and clear cell histology and radical
8 hysterectomy with pelvic and para-aortic lymphadenectomy for stage II.
9 Adjuvant platinum-based chemotherapy was considered the standard treatment for
10 high-risk patients. For different reasons, not all patients received adjuvant
11 chemotherapy. Clinical outcomes are reported for the entire cohort and separately for
12 patients treated with hysterectomy, bilateral salpingo-oophorectomy and at least
13 pelvic lymphadenectomy with or without adjuvant chemotherapy. Patients were
14 monitored every three months during the first two years, every six months for the
15 following three years, and then annually at Oslo University Hospital or their local
16 hospital. Visits included thorough clinical examination and vaginal ultrasound,
17 supplemented by CT or MR scan on clinical indication.

18

19 **Statistical analyses**

20 Continuous variables were described with median and range. Categorical variables
21 were presented with counts and proportions. Crude recurrence rates are given as the
22 proportion of patients diagnosed with relapse during follow-up time. Differences
23 between proportions were assessed by the chi² test.

24 For disease-free survival (DFS), follow-up time was calculated from the date of EC
25 diagnosis until the date of relapse, date of death from any cause or end of follow-up,
26 August 31, 2014, whichever occurred first. Death without prior relapse was treated as
27 event in the analysis of DFS. For overall survival (OS), follow-up time was calculated
28 from the date of EC diagnosis until date of death from any cause or end of follow-up,
29 whichever occurred first. Survival curves were plotted with the Kaplan-Meier method.
30 We calculated 3 year disease-free survival and 3 year overall survival with 95%
31 confidence intervals (CI). All estimates were calculated for the cohort as a whole, and
32 separately for the groups that received and not received adjuvant chemotherapy. For
33 patients with stage IIIc disease, analyses were conducted according to histological
34 subtype (grade 1/2 endometrioid EC versus grade 3 endometrioid/type II EC).

1 The analyses were performed using IBM SPSS version 23 (SPSS, Chicago, IL) and
2 the STATA statistical package, version 11.0, (Stata Corp LP, Texas, USA).

3

4 **RESULTS**

5 The entire database comprised 934 surgically managed EC patients. Of those, 230
6 patients with median age of 69 years (range 36-89 years) fulfilled the inclusion
7 criteria for this analysis.

8 Baseline characteristics and treatment details are given in Table 1. Median follow up
9 time was 4.16 years (range 0.4-8.8). Among those who underwent lymphadenectomy,
10 the median number of removed lymph nodes was 17 (range 0-47) in the pelvis and 6
11 (0-27) in the para-aortic region. The total number of patients who underwent pelvic
12 lymphadenectomy was 203/230 (88.2%) and 136/230 (59.1%) underwent para-aortic
13 lymphadenectomy.

14 Postoperatively, 155 (67.4%) were treated with chemotherapy alone, 64 (27.8%)
15 patients were observed without further treatment, 9 (3.9%) were treated with external
16 beam radiation therapy (EBRT) (one with EBRT and brachytherapy) and 2 (0.9%)
17 received both chemotherapy (one of those received only one cycle) and EBRT.

18

19 *Adherence to institutional guidelines*

20 Omentectomy was performed in 42/54 (77.8%) of patients with serous EC, 17/18
21 (94.4%) with clear cell EC and 29/42 (69%) of patients with mixed histology with a
22 serous or clear cell component. For patients who received postoperative
23 chemotherapy alone (67.4%), the following chemotherapy regimens were
24 administered: Paclitaxel/carboplatin (TC) (n=79), paclitaxel/epirubicin/carboplatin
25 (TEC) (n=61), epirubicin/carboplatin (n=1), cisplatin/paclitaxel (n=1), epirubicin single
26 (n=1) and carboplatin single (n=4). Mean number of cycles was 5.5 and 80.7% of the
27 patients received six cycles.

28 Compliance with institutional guidelines related to FIGO stage is shown in Table 2. In
29 stage I, 16% were not staged and 31% did not receive any adjuvant treatment. In
30 stage II 21% were not staged and 60% did not receive any adjuvant treatment. In
31 stage IIIC 10% did not receive adjuvant treatment.

32

33 *Clinical outcome of patients treated according to institutional guidelines*

1 Of the 230 patients, 146 (63.5%) received treatment according to institutional
2 guidelines with at least pelvic lymphadenectomy and adjuvant chemotherapy with a
3 median age at diagnosis of 67 years (range 35-84 years).
4 In total, 37 (25.3%) patients recurred (Table 3). In stage I 6 patients recurred (10%),
5 with 2 (3.3%) isolated recurrences either in the vagina or in the pelvis and 4 (6.7%)
6 distant failures. Three of the distant recurrences involved distant sites only (two
7 patients with lung metastases, one with recurrence in the upper abdomen). In stage
8 II, only one patient (10%) recurred, with extra pelvic disease. In stage III, 30 (39.5%)
9 patients recurred, 6 (7.9%) with recurrence isolated in the vagina and 24 (31.6%)
10 with distant disease. Of the distant metastases only two were restricted to the para-
11 aortic lymph nodes, two were distant metastases only while the remaining vast
12 majority developed both distant and pelvic/vaginal metastases
13 The 3-year DFS was 92% for stage I (95% CI: 79-97%), 80% (95% CI: 41-95%) for
14 stage II and 60% (95% CI: 48%-70%) for stage IIIc disease (Fig. 1a). The 3-year OS
15 was 98% for stage I (95% CI: 87-100%), 80% for stage II (95% CI: 41-95%) and 83%
16 (95% CI: 73-90%) for stage IIIc.

17
18 The localization of recurrence in patients with stage IIIc disease was further analyzed
19 according to histologic subtype. Both frequency and localization of relapse seem to
20 differ by histological subtype, although the differences did not reach statistical
21 significance. In patients with grade 1/2 endometrioid EC (n=28), 8 (28.6%) recurred,
22 half of them in the vagina only. In grade 3 endometrioid or type II EC (n=43) 19
23 (44.2%) patients recurred (p=0.154). One patient recurred in the vagina only and one
24 had a recurrence restricted to the para-aortic lymph nodes. The remaining vast
25 majority developed distant disease. The 3-year DFS was 71% (95% CI: 50-84%) for
26 grade 1/2 endometrioid tumors compared to 54% (95% CI: 38-68%) for patients with
27 grade 3/type II tumors. The 3-year OS for grade 1/2 tumors was 92% (95% CI: 73-
28 98%) and 76% (95% CI: 60-86%) for grade 3/type II EC tumors.

29 30 *Clinical outcome of patients after surgical treatment only*

31 In our cohort 49 patients underwent pelvic lymphadenectomy but did not receive
32 adjuvant chemotherapy. The reasons, when given in the medical records, mainly
33 included complicating comorbidities or age. These patients were consequently
34 considered unfit for any adjuvant treatment. Four patients refused all further

1 treatment. A total of 19 patients (38.8%) recurred (table 4). Isolated vaginal
2 recurrence occurred in 12 (24.5%), pelvic recurrence in 2 (4.1%) and extra-pelvic
3 disease in 5 (10.2%) of these patients. The 3-year overall DFS and OS was 45%
4 (95% CI: 30-59%) and 71% (95% CI: 55-81%), respectively.

5

6 *Clinical outcome of the whole cohort*

7 In the whole study cohort 68 (29.6%) patients recurred. Recurrences were localized
8 in the vagina in 9.6% (22/230), in the pelvis in 1.7% (4/230) and extra-pelvic in 18.3%
9 (42/230) of the patients (Table 5). The 3-year DFS was 79% for stage I (95% CI:
10 69-86%), 54% (95% CI: 38-68%) for stage II and 55% for stage IIIc (95% CI:
11 44-65%)
12 (Fig. 1b).

13 Sixty-five patients died during follow-up, and the 3-year overall survival (OS) was
14 85% for stage I (95% CI: 75-91%), 78% for stage II (95% CI: 63-88%) and 78%
15 (95%CI: 68-85%) for stage IIIc.

16

17 **DISCUSSION**

18 Our institutional approach of adjuvant chemotherapy only to patients with high-risk
19 endometrial cancer yields acceptable disease free- and overall survival. In particular
20 we observed very few local or loco-regional recurrences. Nevertheless the prognosis
21 of node-positive patients remains poor, also after chemotherapy. It seems that
22 patients with stage IIIc disease of endometrioid type with poor differentiation or type
23 II histology were at particularly high risk of distant recurrence and death despite
24 chemotherapy.

25

26 The treatment for patients with high-risk endometrial cancer still needs to be
27 improved. Although several studies have attempted to identify the best approach,
28 inter-study comparison is hampered by the diversity in patient population. The
29 majority of studies are of non-randomized design with heterogeneous treatment
30 regimens applied. Our institutional guidelines are building on the fact that no study to
31 date has provided evidence that adjuvant RT increases survival. The PORTEC III
32 study reported significant improvement in 5-year failure-free survival from 68.6% to
33 75.5%, mainly driven by the positive results in stage III disease. Besides the
34 improvement in loco-regional control, no survival benefit could be demonstrated in
any subgroup⁸. The GOG 258 study included more advanced disease and could not

1 detect any significant improvement of DFS when chemoradiation was added to
2 chemotherapy⁷. Rather, concerns exist regarding toxicity⁶ especially when combined
3 with chemotherapy and also regarding the increased risk of secondary malignancy¹⁵.
4 On the other hand, the risk of loco-regional relapse may be higher when radiotherapy
5 is omitted with reported relapse rates as high as 39% after chemotherapy only in
6 patients with optimally resected stage III disease¹¹ with half of them being located in
7 the pelvis/vagina. Brachytherapy, which is associated with less toxicity, may be
8 sufficient to prevent vaginal relapse in some patients¹². The recently released ESGO
9 guidelines^{9,10} still recommend administration of radiotherapy despite the lack of
10 benefit for survival, and regard brachytherapy as an alternative for node negative
11 high risk stage I and selected stage II patients. Our rates of vaginal/pelvic recurrence
12 of 3% in stage I and 8% in stage IIIC after chemotherapy were low compared to
13 these reports. Our figures are comparable to or lower than those reported after pelvic
14 radiation, with loco-regional recurrences in 7-16% of their patients^{4,16}. There is
15 evidence that vaginal/pelvic recurrences can be cured with radiotherapy once they
16 occur, although this has only been shown for patients with early stage disease^{13,16}.
17 Our excellent survival rates in patients with stage I disease may support this. Another
18 argument for reserving radiotherapy for patients with recurrent disease is the fact that
19 RT will not prevent all loco-regional relapses. So if these patients are irradiated
20 upfront, relapses may then be hard to cure.

21 The vast majority of recurrences in our study sample were distant metastases
22 despite chemotherapy, which is in line with previous reports on high-risk early stage
23 and stage IIIC endometrial cancer^{6,11,17}. The poor survival of patients with positive
24 lymph nodes at the time of diagnosis despite treatment with chemotherapy highlights
25 the need for improved systemic treatment strategies in these patients.

26 Intensification of the regimen by combining chemotherapy and radiation did not
27 improve survival but rather increased toxicity^{7,8} and may lead to lower completion
28 rates, especially of the chemotherapy component⁶. In our cohort, completion rate of
29 chemotherapy was high favoring the administration of only one modality. The fact
30 that a considerable proportion of patients in our study did not receive the institutional
31 standard treatment is in line with recent reports from the Dutch Cancer Registry
32 where compliance of physicians to adjuvant therapy guidelines were remarkably low,
33 particularly in patients with high risk disease¹⁸. The poor outcome of patients with

1 stage II disease is worrying and highlights the importance of compliance to treatment
2 guidelines. Toxicity is obviously a concern in patients with high-risk EC who often
3 belong to an elderly, comorbid patient population mainly due to limited data on
4 chemotherapy tolerance in these patients. In line with the ESGO guidelines,
5 brachytherapy may be discussed with selected patients unfit for systemic therapy but
6 the benefit for local control only needs to be balanced against careful observation
7 with treatment at the time of relapse.

8 Our subgroup analysis according to histology confirmed the particular aggressive
9 behavior of type II and poorly differentiated endometrioid tumors¹⁹. There is evolving
10 data on the molecular subtypes of endometrial cancer underlining the heterogeneity
11 and overlapping profiles in type I and II EC. Copy number high tumors have been
12 pointed out as a group with high prevalence of p53 mutation and poor prognosis in
13 several data sets^{20,21} Understanding the molecular drivers in high-risk patients may
14 eventually enable us to develop targeted treatment options.

15 The strength of this study is the pathological review of all cases at the time of
16 diagnosis by a pathologist specialized in gynecologic pathology (B.D). Our hospital is
17 the referral center for patients with relapsed disease in the region, and we are
18 therefore confident that our follow-up data for recurrence are complete. The study is
19 limited by its retrospective design and the low number of patients available for
20 analysis when the cohort is broken down to subgroups. A diversity of adjuvant
21 treatment were given and a variety of chemotherapy regimens were applied, but the
22 vast majority included a platinum/paclitaxel combination, which is considered
23 standard of care for this patient group¹⁰. The analysis by histological subtype of
24 lymph node positive patients is hampered by small numbers and precludes definite
25 conclusions.

26 In light of the acceptable pelvic recurrence rates, adjuvant treatment with
27 chemotherapy alone seems safe. Rather than intensifying current treatment with
28 radiation, there is an urgent need for prospective studies evaluating novel treatment
29 strategies for patients with high-risk endometrial cancer. Molecular validation studies
30 with comprehensive clinical data will be necessary to identify patients at truly high
31 risk of relapse.

1 INTRODUCTION

2 Endometrial cancer (EC) is the most common gynecological malignancy in the
3 Western world. The continuously increasing incidence in Western countries is mostly
4 attributable to the increase in prevalence of risk factors in the population such as
5 obesity and diabetes¹. Patients with early stage disease often have excellent
6 prognosis, with a 10-year overall survival rate exceeding 80%. Still, there are
7 subgroups with a high risk for occult micro-metastatic disease. Traditionally,
8 endometrial cancers have been considered to be resistant to chemotherapy and
9 most high-risk patients have been treated with adjuvant radiotherapy (RT). This view
10 has gradually changed since the publication of GOG-122 reporting improved both
11 disease-free survival (DFS) and overall survival (OS) for this group of patients after
12 chemotherapy compared to whole abdominal irradiation (WAI) in patients with stage
13 III and IV endometrial cancer². Since then, several randomized studies have tried to
14 clarify the role of adjuvant chemotherapy in endometrial cancer. Three subsequent
15 studies compared combination chemotherapy with adjuvant radiation to the pelvis in
16 patients with early stage high-risk or advanced stage disease. All three studies failed
17 to show significant differences in DFS or OS between the arms³⁻⁵ but they were not
18 designed to potentially identify a subgroup of patients that may benefit from either of
19 the treatment modalities.

20 In a pooled analysis of two randomized trials (NSGOEC-9501/EORTC-55991 and
21 MaNGO ILIAD-III) it was shown that the addition of chemotherapy sequential to RT
22 versus RT alone significantly increased DFS while the increase in OS did not reach
23 statistical significance⁶. The combined treatment was associated with increased
24 morbidity and a higher rate of treatment discontinuation. There was no significant
25 difference in the patterns of relapse between the arms. A large randomized study
26 (GOG 258) failed to show a difference in survival between chemotherapy versus
27 chemoradiation followed by chemotherapy in optimally debulked stage III and IV⁷.
28 The randomized Portec 3 study randomized patients in stage I, II and III without
29 residual disease to radiation alone or chemoradiation followed by chemotherapy. The
30 benefit in 5-year failure free survival with the combination was mainly driven by the
31 positive results for patients with stage III disease, but did not translate into a benefit
32 in overall survival⁸. Despite these studies, newly released ESGO guidelines^{9,10}
33 advocate for the administration of adjuvant radiotherapy in high-risk disease.

1 There have been constant concerns about the potentially increased risk of
2 pelvic/vaginal relapse in patients treated with chemotherapy only. In a retrospective
3 study where patients with stage IIIC disease treated with either chemotherapy alone,
4 radiation alone or a combination of both, pelvic relapse rates were 39%, 29% and
5 27%, respectively¹¹. However, most relapses in high-risk EC patients occur outside
6 the pelvis irrespective of the kind of adjuvant treatment¹¹. Vaginal recurrences can be
7 effectively salvaged by modern radiotherapy¹² and the omission of adjuvant
8 radiotherapy at least in early stage EC has not been shown to diminish long-term
9 survival¹³.

10 At the Norwegian Radium Hospital, patients with high-risk stage I/II and IIIC EC have
11 since 2005 therefore routinely been treated with chemotherapy only, omitting
12 radiotherapy. Here we report the oncological outcomes of this treatment policy.
13

14 **MATERIAL AND METHODS**

15

16 **Patients and follow-up**

17 This is an institutional retrospective study of a cohort of all endometrial cancer
18 patients, treated at the Oslo University Hospital (The Norwegian Radium Hospital,
19 Ullevål University Hospital and Rikshospitalet) between November 2005 and October
20 2012. Patients were selected from a validated quality assurance database, providing
21 detailed information on the primary diagnosis, the preoperative work-up, comorbidity,
22 surgical treatment, adjuvant treatment, incident relapse and localization of relapse.
23 All specimens underwent central histopathological review by a pathologist
24 specialized in gynecologic pathology at the Norwegian Radium Hospital at the time of
25 diagnosis. Individual survival data were available through linkage to Statistics Norway.
26 Stage of the disease at initial surgery was recoded to match the International
27 Federation of Gynecology and Obstetrics (FIGO) 2009 revised staging¹⁴. We
28 included all patients with (1) FIGO stage I, grade 3, endometrioid endometrial
29 carcinoma with myometrial invasion $\geq 50\%$, (2) FIGO stage I serous and clear cell
30 endometrial cancer (pure or mixed with at least 50% serous or clear cell component)
31 of any myometrial invasion, (3) endometrial cancer with cervical stromal invasion of
32 any histology (FIGO stage II) and (4) lymph node positive endometrial cancer of any
33 histology (FIGO stage IIIC). Patients with positive lymph nodes were further analyzed
34 according to histological subtype (grade 1 or 2 endometrioid adenocarcinoma versus

1 grade 3 endometrioid adenocarcinoma or serous and clear cell carcinomas).
2 Sarcomas or carcinosarcomas were excluded from the analyses, as well as patients
3 with synchronous ovarian cancer (n=6) or neoadjuvant chemotherapy (n=4). All
4 patients underwent surgical treatment with at least total hysterectomy and bilateral
5 salpingo-oophorectomy. Institutional guidelines considered standard treatment to be
6 pelvic lymphadenectomy and para-aortic lymphadenectomy up to the renal veins for
7 high-risk stage I, omentectomy for serous and clear cell histology and radical
8 hysterectomy with pelvic and para-aortic lymphadenectomy for stage II.
9 Adjuvant platinum-based chemotherapy was considered the standard treatment for
10 high-risk patients. For different reasons, not all patients received adjuvant
11 chemotherapy. Clinical outcomes are reported for the entire cohort and separately for
12 patients treated with hysterectomy, bilateral salpingo-oophorectomy and at least
13 pelvic lymphadenectomy with or without adjuvant chemotherapy. Patients were
14 monitored every three months during the first two years, every six months for the
15 following three years, and then annually at Oslo University Hospital or their local
16 hospital. Visits included thorough clinical examination and vaginal ultrasound,
17 supplemented by CT or MR scan on clinical indication.

18

19 **Statistical analyses**

20 Continuous variables were described with median and range. Categorical variables
21 were presented with counts and proportions. Crude recurrence rates are given as the
22 proportion of patients diagnosed with relapse during follow-up time. Differences
23 between proportions were assessed by the χ^2 test.

24 For disease-free survival (DFS), follow-up time was calculated from the date of EC
25 diagnosis until the date of relapse, date of death from any cause or end of follow-up,
26 August 31, 2014, whichever occurred first. Death without prior relapse was treated as
27 event in the analysis of DFS. For overall survival (OS), follow-up time was calculated
28 from the date of EC diagnosis until date of death from any cause or end of follow-up,
29 whichever occurred first. Survival curves were plotted with the Kaplan-Meier method.
30 We calculated 3 year disease-free survival and 3 year overall survival with 95%
31 confidence intervals (CI). All estimates were calculated for the cohort as a whole, and
32 separately for the groups that received and not received adjuvant chemotherapy. For
33 patients with stage IIIc disease, analyses were conducted according to histological
34 subtype (grade 1/2 endometrioid EC versus grade 3 endometrioid/type II EC).

1 The analyses were performed using IBM SPSS version 23 (SPSS, Chicago, IL) and
2 the STATA statistical package, version 11.0, (Stata Corp LP, Texas, USA).

3

4 **RESULTS**

5 The entire database comprised 934 surgically managed EC patients. Of those, 230
6 patients with median age of 69 years (range 36-89 years) fulfilled the inclusion
7 criteria for this analysis.

8 Baseline characteristics and treatment details are given in Table 1. Median follow up
9 time was 4.16 years (range 0.4-8.8). Among those who underwent lymphadenectomy,
10 the median number of removed lymph nodes was 17 (range 0-47) in the pelvis and 6
11 (0-27) in the para-aortic region. The total number of patients who underwent pelvic
12 lymphadenectomy was 203/230 (88.2%) and 136/230 (59.1%) underwent para-aortic
13 lymphadenectomy.

14 Postoperatively, 155 (67.4%) were treated with chemotherapy alone, 64 (27.8%)
15 patients were observed without further treatment, 9 (3.9%) were treated with external
16 beam radiation therapy (EBRT) (one with EBRT and brachytherapy) and 2 (0.9%)
17 received both chemotherapy (one of those received only one cycle) and EBRT.

18

19 *Adherence to institutional guidelines*

20 Omentectomy was performed in 42/54 (77.8%) of patients with serous EC, 17/18
21 (94.4%) with clear cell EC and 29/42 (69%) of patients with mixed histology with a
22 serous or clear cell component. For patients who received postoperative
23 chemotherapy alone (67.4%), the following chemotherapy regimens were
24 administered: Paclitaxel/carboplatin (TC) (n=79), paclitaxel/epirubicin/carboplatin
25 (TEC) (n=61), epirubicin/carboplatin (n=1), cisplatin/paclitaxel (n=1), epirubicin single
26 (n=1) and carboplatin single (n=4). Mean number of cycles was 5.5 and 80.7% of the
27 patients received six cycles.

28 Compliance with institutional guidelines related to FIGO stage is shown in Table 2. In
29 stage I, 16% were not staged and 31% did not receive any adjuvant treatment. In
30 stage II 21% were not staged and 60% did not receive any adjuvant treatment. In
31 stage IIIC 10% did not receive adjuvant treatment.

32

33 *Clinical outcome of patients treated according to institutional guidelines*

1 Of the 230 patients, 146 (63.5%) received treatment according to institutional
2 guidelines with at least pelvic lymphadenectomy and adjuvant chemotherapy with a
3 median age at diagnosis of 67 years (range 35-84 years).
4 In total, 37 (25.3%) patients recurred (Table 3). In stage I 6 patients recurred (10%),
5 with 2 (3.3%) isolated recurrences either in the vagina or in the pelvis and 4 (6.7%)
6 distant failures. Three of the distant recurrences involved distant sites only (two
7 patients with lung metastases, one with recurrence in the upper abdomen). In stage
8 II, only one patient (10%) recurred, with extra pelvic disease. In stage III, 30 (39.5%)
9 patients recurred, 6 (7.9%) with recurrence isolated in the vagina and 24 (31.6%)
10 with distant disease. Of the distant metastases only two were restricted to the para-
11 aortic lymph nodes, two were distant metastases only while the remaining vast
12 majority developed both distant and pelvic/vaginal metastases
13 The 3-year DFS was 92% for stage I (95% CI: 79-97%), 80% (95% CI: 41-95%) for
14 stage II and 60% (95% CI: 48%-70%) for stage IIIc disease (Fig. 1a). The 3-year OS
15 was 98% for stage I (95% CI: 87-100%), 80% for stage II (95% CI: 41-95%) and 83%
16 (95% CI: 73-90%) for stage IIIc.

17
18 The localization of recurrence in patients with stage IIIc disease was further analyzed
19 according to histologic subtype. Both frequency and localization of relapse seem to
20 differ by histological subtype, although the differences did not reach statistical
21 significance. In patients with grade 1/2 endometrioid EC (n=28), 8 (28.6%) recurred,
22 half of them in the vagina only. In grade 3 endometrioid or type II EC (n=43) 19
23 (44.2%) patients recurred (p=0.154). One patient recurred in the vagina only and one
24 had a recurrence restricted to the para-aortic lymph nodes. The remaining vast
25 majority developed distant disease. The 3-year DFS was 71% (95% CI: 50-84%) for
26 grade 1/2 endometrioid tumors compared to 54% (95% CI: 38-68%) for patients with
27 grade 3/type II tumors. The 3-year OS for grade 1/2 tumors was 92% (95% CI: 73-
28 98%) and 76% (95% CI: 60-86%) for grade 3/type II EC tumors.

29
30 *Clinical outcome of patients after surgical treatment only*

31 In our cohort 49 patients underwent pelvic lymphadenectomy but did not receive
32 adjuvant chemotherapy. The reasons, when given in the medical records, mainly
33 included complicating comorbidities or age. These patients were consequently
34 considered unfit for any adjuvant treatment. Four patients refused all further

1 treatment. A total of 19 patients (38.8%) recurred (table 4). Isolated vaginal
2 recurrence occurred in 12 (24.5%), pelvic recurrence in 2 (4.1%) and extra-pelvic
3 disease in 5 (10.2%) of these patients. The 3-year overall DFS and OS was 45%
4 (95% CI: 30-59%) and 71% (95% CI: 55-81%), respectively.

5

6 *Clinical outcome of the whole cohort*

7 In the whole study cohort 68 (29.6%) patients recurred. Recurrences were localized
8 in the vagina in 9.6% (22/230), in the pelvis in 1.7% (4/230) and extra-pelvic in 18.3%
9 (42/230) of the patients (Table 5). The 3-year DFS was 79% for stage I (95% CI: 69-
10 86%), 54% (95% CI: 38-68%) for stage II and 55% for stage IIIc (95% CI: 44-65%)
11 (Fig. 1b).

12 Sixty-five patients died during follow-up, and the 3-year overall survival (OS) was
13 85% for stage I (95% CI: 75-91%), 78% for stage II (95% CI: 63-88%) and 78%
14 (95%CI: 68-85%) for stage IIIc.

15

16 **DISCUSSION**

17 Our institutional approach of adjuvant chemotherapy only to patients with high-risk
18 endometrial cancer yields acceptable disease free- and overall survival. In particular
19 we observed very few local or loco-regional recurrences. Nevertheless the prognosis
20 of node-positive patients remains poor, also after chemotherapy. It seems that
21 patients with stage IIIc disease of endometrioid type with poor differentiation or type
22 II histology were at particularly high risk of distant recurrence and death despite
23 chemotherapy.

24

25 The treatment for patients with high-risk endometrial cancer still needs to be
26 improved. Although several studies have attempted to identify the best approach,
27 inter-study comparison is hampered by the diversity in patient population. The
28 majority of studies are of non-randomized design with heterogeneous treatment
29 regimens applied. Our institutional guidelines are building on the fact that no study to
30 date has provided evidence that adjuvant RT increases survival. The PORTEC III
31 study reported significant improvement in 5-year failure-free survival from 68.6% to
32 75.5%, mainly driven by the positive results in stage III disease. Besides the
33 improvement in loco-regional control, no survival benefit could be demonstrated in
34 any subgroup⁸. The GOG 258 study included more advanced disease and could not

1 detect any significant improvement of DFS when chemoradiation was added to
2 chemotherapy⁷. Rather, concerns exist regarding toxicity⁶ especially when combined
3 with chemotherapy and also regarding the increased risk of secondary malignancy¹⁵.
4 On the other hand, the risk of loco-regional relapse may be higher when radiotherapy
5 is omitted with reported relapse rates as high as 39% after chemotherapy only in
6 patients with optimally resected stage III disease¹¹ with half of them being located in
7 the pelvis/vagina. Brachytherapy, which is associated with less toxicity, may be
8 sufficient to prevent vaginal relapse in some patients¹². The recently released ESGO
9 guidelines^{9,10} still recommend administration of radiotherapy despite the lack of
10 benefit for survival, and regard brachytherapy as an alternative for node negative
11 high risk stage I and selected stage II patients. Our rates of vaginal/pelvic recurrence
12 of 3% in stage I and 8% in stage IIIC after chemotherapy were low compared to
13 these reports. Our figures are comparable to or lower than those reported after pelvic
14 radiation, with loco-regional recurrences in 7-16% of their patients^{4,16}. There is
15 evidence that vaginal/pelvic recurrences can be cured with radiotherapy once they
16 occur, although this has only been shown for patients with early stage disease^{13,16}.
17 Our excellent survival rates in patients with stage I disease may support this. Another
18 argument for reserving radiotherapy for patients with recurrent disease is the fact that
19 RT will not prevent all loco-regional relapses. So if these patients are irradiated
20 upfront, relapses may then be hard to cure.

21 The vast majority of recurrences in our study sample were distant metastases
22 despite chemotherapy, which is in line with previous reports on high-risk early stage
23 and stage IIIC endometrial cancer^{6,11,17}. The poor survival of patients with positive
24 lymph nodes at the time of diagnosis despite treatment with chemotherapy highlights
25 the need for improved systemic treatment strategies in these patients.

26 Intensification of the regimen by combining chemotherapy and radiation did not
27 improve survival but rather increased toxicity^{7,8} and may lead to lower completion
28 rates, especially of the chemotherapy component⁶. In our cohort, completion rate of
29 chemotherapy was high favoring the administration of only one modality. The fact
30 that a considerable proportion of patients in our study did not receive the institutional
31 standard treatment is in line with recent reports from the Dutch Cancer Registry
32 where compliance of physicians to adjuvant therapy guidelines were remarkably low,
33 particularly in patients with high risk disease¹⁸. The poor outcome of patients with

1 stage II disease is worrying and highlights the importance of compliance to treatment
2 guidelines. Toxicity is obviously a concern in patients with high-risk EC who often
3 belong to an elderly, comorbid patient population mainly due to limited data on
4 chemotherapy tolerance in these patients. In line with the ESGO guidelines,
5 brachytherapy may be discussed with selected patients unfit for systemic therapy but
6 the benefit for local control only needs to be balanced against careful observation
7 with treatment at the time of relapse.

8 Our subgroup analysis according to histology confirmed the particular aggressive
9 behavior of type II and poorly differentiated endometrioid tumors¹⁹. There is evolving
10 data on the molecular subtypes of endometrial cancer underlining the heterogeneity
11 and overlapping profiles in type I and II EC. Copy number high tumors have been
12 pointed out as a group with high prevalence of p53 mutation and poor prognosis in
13 several data sets^{20,21} Understanding the molecular drivers in high-risk patients may
14 eventually enable us to develop targeted treatment options.

15 The strength of this study is the pathological review of all cases at the time of
16 diagnosis by a pathologist specialized in gynecologic pathology (B.D). Our hospital is
17 the referral center for patients with relapsed disease in the region, and we are
18 therefore confident that our follow-up data for recurrence are complete. The study is
19 limited by its retrospective design and the low number of patients available for
20 analysis when the cohort is broken down to subgroups. A diversity of adjuvant
21 treatment were given and a variety of chemotherapy regimens were applied, but the
22 vast majority included a platinum/paclitaxel combination, which is considered
23 standard of care for this patient group¹⁰. The analysis by histological subtype of
24 lymph node positive patients is hampered by small numbers and precludes definite
25 conclusions.

26 In light of the acceptable pelvic recurrence rates, adjuvant treatment with
27 chemotherapy alone seems safe. Rather than intensifying current treatment with
28 radiation, there is an urgent need for prospective studies evaluating novel treatment
29 strategies for patients with high-risk endometrial cancer. Molecular validation studies
30 with comprehensive clinical data will be necessary to identify patients at truly high
31 risk of relapse.

1 **References**

- 2 1. Lindemann K, Eskild A, Vatten LJ, et al. Endometrial cancer incidence trends
3 in Norway during 1953–2007 and predictions for 2008–2027. *International*
4 *Journal of Cancer* 2010;127(11):2661-68.
- 5 2. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-
6 abdominal irradiation versus doxorubicin and cisplatin chemotherapy in
7 advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
8 *Journal of clinical oncology* 2006;24(1):36-44.
- 9 3. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic
10 radiotherapy versus cisplatin-based combined chemotherapy in patients with
11 intermediate- and high-risk endometrial cancer: a Japanese Gynecologic
12 Oncology Group study. *Gynecologic oncology* 2008;108(1):226-33.
- 13 4. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in
14 high-risk endometrial carcinoma: results of a randomised trial. *Br J Cancer*
15 2006;95(3):266-71.
- 16 5. Kuoppala T, Maenpaa J, Tomas E, et al. Surgically staged high-risk
17 endometrial cancer: randomized study of adjuvant radiotherapy alone vs.
18 sequential chemo-radiotherapy. *Gynecologic oncology* 2008;110(2):190-5.
- 19 6. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant
20 chemotherapy and radiotherapy in endometrial cancer--results from two
21 randomised studies. *Eur J Cancer* 2010;46(13):2422-31.
- 22 7. Matei D, Filiaci VL, Randall M, et al. A randomized phase III trial of cisplatin
23 and tumor volume directed irradiation followed by carboplatin and paclitaxel vs.
24 carboplatin and paclitaxel for optimally debulked, advanced endometrial
25 carcinoma. *Journal of Clinical Oncology* 2017;35(15_suppl):5505-05.

- 1 8. De Boer SM, Powell ME, Mileskin LR, et al. PORTEC Study Group;. Final
2 results of the international randomized PORTEC-3 trial of adjuvant
3 chemotherapy and radiation therapy (RT) versus RT alone for women with
4 high-risk endometrial cancer. *J Clin Oncol* 35, 2017 (suppl; abstr 5502)
- 5 9. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus
6 Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
7 *Annals of oncology* 2016;27(1):16-41.
- 8 10. Colombo N, Preti E, Landoni F, et al. on behalf of the ESMO Guidelines
9 Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for
10 diagnosis, treatment and follow-up. *Annals of Oncology* 2013; 24 (Supplement
11 6)
- 12 11. Secord AA, Geller MA, Broadwater G, et al. A multicenter evaluation of
13 adjuvant therapy in women with optimally resected stage IIIC endometrial
14 cancer. *Gynecologic oncology* 2013;128(1):65-70.
- 15 12. Vargo JA, Kim H, Houser CJ, et al. Definitive salvage for vaginal recurrence of
16 endometrial cancer: the impact of modern intensity-modulated-radiotherapy
17 with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk
18 stratification. *Radiotherapy and oncology* 2014;113(1):126-31.
- 19 13. Ortoft G, Hansen ES, Bertelsen K. Omitting adjuvant radiotherapy in
20 endometrial cancer increases the rate of locoregional recurrences but has no
21 effect on long-term survival: the Danish Endometrial Cancer Study.
22 *International journal of gynecological cancer* 2013;23(8):1429-37.
- 23 14. Pecorelli S, Zigliani L, Odicino F, et al. Revised FIGO staging for carcinoma of
24 the vulva, cervix, and endometrium. *International journal of gynaecology and*

- 1 obstetrics: the official organ of the International Federation of Gynaecology
2 and Obstetrics 2009;105(2):103-4.
- 3 15. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after
4 pelvic radiation for early-stage endometrial cancer. *J Clin Oncol*
5 2013;31(31):3951-6.
- 6 16. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy
7 outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. *Int J*
8 *Radiat Oncol Biol Phys* 2011;81(4):e631-8.
- 9 17. Randall ME, Spirtos NM, Dvoretzky P. Whole abdominal radiotherapy versus
10 combination chemotherapy with doxorubicin and cisplatin in advanced
11 endometrial carcinoma (phase III): Gynecologic Oncology Group Study No.
12 122. *J Natl Cancer Inst Monogr* 1995(19):13-5.
- 13 18. Eggink FA, Mom CH, Boll D, et al. Compliance with adjuvant treatment
14 guidelines in endometrial cancer: room for improvement in high risk patients.
15 *Gynecologic oncology* 2017;146(2):380-85.
- 16 19. Bakkum-Gamez JN, Mariani A, Dowdy SC, et al. Efficacy of contemporary
17 chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.
18 *Gynecologic oncology* 2014;132(3):578-84.
- 19 20. Integrated Genomic Characterization of Endometrial Carcinoma. *Nature*
20 2013;497(7447):67-73.
- 21 21. Le Gallo M, Bell DW. The Emerging Genomic Landscape of Endometrial
22 Cancer. *Clinical chemistry* 2014;60(1):98-110.

23
24
25
26

1 **Figure legends**

2

3 Figure 1a: Kaplan Meier estimates of disease-free survival by FIGO stage
4 in patients treated with at least pelvic lymphadenectomy and adjuvant
5 chemotherapy (N=146)

6

7 Figure 1b: Kaplan Meier estimates of disease-free survival by FIGO stage
8 in all patients (N=230)

9


10

11

Figure 1


A

Disease-free survival




Number at risk

Stage I	60	51	30	12	3	0
Stage II	10	8	6	4	1	0
Stage IIIc	76	50	35	20	7	0



B

Disease-free survival



Number at risk

Stage I	98	77	48	22	9	0
Stage II	42	26	19	13	7	0
Stage IIIc	90	54	37	21	8	0




Table 1: Baseline characteristics (N=230)

Patient characteristic	Median (range)
Age	69 (36-89)
	No of patients (%)
Diabetes	
Yes	25 (10.9)
No	201 (87.4)
Missing	4 (1.7)
Smoking	
Yes	31 (13.5)
No	141 (61.3)
Missing	58 (25.2)
Histology	
Endometrioid	109 (47.4)
Serous/clear cell/mixed	114 (49.6)
Other	5 (2.2)
Unclassified	2 (0.9)
Stage	
Ia	55 (23.9)
Ib	43 (18.7)
II	42 (18.3)
IIIc	90 (39.1)
Lymphadenectomy by stage	
Ia	n=55
Not staged	7 (12.7)
At least pelvis	48 (87.3)
Pelvis/PA	34 (61.8)
Ib	n=43
Not staged	9 (20.9)
At least pelvis	34 (79.1)
Pelvis/PA	25 (58.1)
II	n=42
Not staged	9 (21.4)
At least pelvis	33 (78.6)
Pelvis/PA	17 (51.5)
IIIc	n=90
Not staged*	2 (2.2)
At least pelvis	88 (97.8)
Pelvis/PA	60 (66.7)
Total pelvic lymphadenectomy	203 (88.2)
Total paraaortic lymphadenectomy	136 (59.1)
Type of surgery	
Abdominal procedure	187 (81.3)
Laparoscopic procedure (included robot)	41 (17.9)
Removed uterus earlier	2 (0.8)
Adjuvant treatment	
No adjuvant treatment	64 (27.8)

Radiotherapy	9 (3.9)
Chemotherapy	155 (67.4)
RT+CT	2 (0.9)

*Not completely staged, but both patients had one metastatic lymph node removed, one pelvic and one para-aortic, respectively.

Table 2: Compliance with institutional guidelines by stage of disease

Surgical treatment	Adjuvant treatment	Stage I n=98 (%)	Stage II n=42 (%)	Stage III n=90 (%)
Staged	CT	60 (66.7)	10 (23.8)	76 (84.4)
	RT	2 (2.2)	3 (7.1)	2 (2.2)
	CT+RT	0	0	1 (1.1)
	No adjuvant treatment	20 (21.7)	20 (47.6)	9 (10)
Not staged	CT	6 (6.7)	1 (2.4)	2 (2.2)*
	RT	0	2 (4.8)	0
	CT+RT	0	1 (2.4)	0
	No adjuvant treatment	10 (11.1)	5 (11.9)	0

Abbreviations: CT=Chemotherapy, RT=Radiotherapy

*Not completely staged, but both patients had one metastatic lymph node removed, one pelvic and one para-aortic, respectively.

Table 3: Frequency and localization of relapse in patients treated with at least pelvic lymphadenectomy and adjuvant chemotherapy (n=146)

Stage	No of patients	Localization of relapse			Total no of relapses (%)
		Vagina	Pelvis	Extra-pelvic	
la	35	0	1	2	3 (8.6)
lb	25	1	0	2	3 (12)
II	10	0	0	1	1 (10)
IIIc	76	6	0	24	30 (39.5)
G1/G2	28	4	0	4	8 (28.6)
G3/type II	43	1	0	18	19 (44.2)
All stages	146	7	1	29	37 (25.3)

Table 4. Frequency and localization of relapse in patients treated with at least pelvic lymphadenectomy without adjuvant chemotherapy (n=49)

Stage	No of patients	Localization of relapse			Total no of relapses (%)
		Vagina	Pelvis	Extra-pelvic	
Ia	13	3	1	0	4 (30.8)
Ib	7	0	0	0	0
II	20	7	1	3	11 (47.8)
IIIc	9	2	0	2	4 (36.4)
All stages	49	12	2	5	19 (38.8)

Table 5: Frequency and localization of relapse in all patients (n=230)

Stage	No of patients	Localization of relapse			Total no of relapses (%)
		Vagina	Pelvis	Extra-pelvic	
Ia	55	4	2	5	11 (20)
Ib	43	2	0	2	4 (9.3)
II	42	8	2	5	15 (35.7)
IIIc	90	8	0	30	38 (42.2)
All stages	230	22	4	42	68 (29.6)